NCT01473381.
Trial name or title | Safety and Efficacy of Vilazodone in Major Depressive Disorder (NCT01473381). |
Methods | Randomised, double‐blind study. |
Participants | Patients aged 18‐70 years, with MDD (according to DSM‐IV criteria). The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration. |
Interventions | Vilazodone Citalopram Placebo |
Outcomes | Primary Outcome Measure: MADRS score at 10 Weeks. |
Starting date | November 2011. |
Contact information | Sandra Beaird, PhD 1‐800‐678‐1605 ext 66297, info@forestpharm.com |
Notes |
DSM‐IV: Diagnostic and Statistical Manual of Mental Disorders
MADRS: Montgomery and Asberg Depression Rating Scale MMD: major depressive disorder MRI: magnetic resonance imaging QIDS‐SR: Quick Inventory of Depressive Symptomatology Self‐Report